vs
Side-by-side financial comparison of ENTEGRIS INC (ENTG) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
ENTEGRIS INC is the larger business by last-quarter revenue ($823.9M vs $493.8M, roughly 1.7× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 6.0%, a 0.8% gap on every dollar of revenue. On growth, Pediatrix Medical Group, Inc. posted the faster year-over-year revenue change (-1.7% vs -3.1%). Over the past eight quarters, ENTEGRIS INC's revenue compounded faster (3.4% CAGR vs -0.1%).
Entegris, Inc. is a supplier of materials for the semiconductor and other high-tech industries. Entegris has approximately 8,000 employees throughout its global operations. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. The company’s corporate headquarters are in Billerica, Massachusetts.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
ENTG vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $823.9M | $493.8M |
| Net Profit | $49.4M | $33.7M |
| Gross Margin | 43.8% | — |
| Operating Margin | 12.7% | 9.9% |
| Net Margin | 6.0% | 6.8% |
| Revenue YoY | -3.1% | -1.7% |
| Net Profit YoY | -51.7% | 10.5% |
| EPS (diluted) | $0.33 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $823.9M | $493.8M | ||
| Q3 25 | $807.1M | $492.9M | ||
| Q2 25 | $792.4M | $468.8M | ||
| Q1 25 | $773.2M | $458.4M | ||
| Q4 24 | $849.8M | $502.4M | ||
| Q3 24 | $807.7M | $511.2M | ||
| Q2 24 | $812.7M | $504.3M | ||
| Q1 24 | $771.0M | $495.1M |
| Q4 25 | $49.4M | $33.7M | ||
| Q3 25 | $70.5M | $71.7M | ||
| Q2 25 | $52.8M | $39.3M | ||
| Q1 25 | $62.9M | $20.7M | ||
| Q4 24 | $102.2M | $30.5M | ||
| Q3 24 | $77.6M | $19.4M | ||
| Q2 24 | $67.7M | $-153.0M | ||
| Q1 24 | $45.3M | $4.0M |
| Q4 25 | 43.8% | — | ||
| Q3 25 | 43.5% | — | ||
| Q2 25 | 44.4% | — | ||
| Q1 25 | 46.1% | — | ||
| Q4 24 | 45.6% | — | ||
| Q3 24 | 46.0% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 12.7% | 9.9% | ||
| Q3 25 | 15.2% | 13.8% | ||
| Q2 25 | 13.4% | 12.8% | ||
| Q1 25 | 15.8% | 7.0% | ||
| Q4 24 | 17.6% | 7.8% | ||
| Q3 24 | 16.9% | 6.6% | ||
| Q2 24 | 16.0% | -31.3% | ||
| Q1 24 | 15.3% | 3.2% |
| Q4 25 | 6.0% | 6.8% | ||
| Q3 25 | 8.7% | 14.5% | ||
| Q2 25 | 6.7% | 8.4% | ||
| Q1 25 | 8.1% | 4.5% | ||
| Q4 24 | 12.0% | 6.1% | ||
| Q3 24 | 9.6% | 3.8% | ||
| Q2 24 | 8.3% | -30.3% | ||
| Q1 24 | 5.9% | 0.8% |
| Q4 25 | $0.33 | $0.40 | ||
| Q3 25 | $0.46 | $0.84 | ||
| Q2 25 | $0.35 | $0.46 | ||
| Q1 25 | $0.41 | $0.24 | ||
| Q4 24 | $0.67 | $0.37 | ||
| Q3 24 | $0.51 | $0.23 | ||
| Q2 24 | $0.45 | $-1.84 | ||
| Q1 24 | $0.30 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $360.4M | $375.2M |
| Total DebtLower is stronger | $3.7B | $570.5M |
| Stockholders' EquityBook value | $4.0B | $865.9M |
| Total Assets | $8.4B | $2.2B |
| Debt / EquityLower = less leverage | 0.94× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $360.4M | $375.2M | ||
| Q3 25 | $399.8M | $340.1M | ||
| Q2 25 | $376.8M | $224.7M | ||
| Q1 25 | $340.9M | $99.0M | ||
| Q4 24 | $329.2M | $229.9M | ||
| Q3 24 | $432.1M | $103.8M | ||
| Q2 24 | $320.0M | $19.4M | ||
| Q1 24 | $340.7M | $8.0M |
| Q4 25 | $3.7B | $570.5M | ||
| Q3 25 | $3.8B | $577.2M | ||
| Q2 25 | $4.0B | $583.9M | ||
| Q1 25 | $4.0B | $590.5M | ||
| Q4 24 | $4.0B | $597.1M | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.1B | — | ||
| Q1 24 | $4.2B | — |
| Q4 25 | $4.0B | $865.9M | ||
| Q3 25 | $3.9B | $890.7M | ||
| Q2 25 | $3.8B | $833.8M | ||
| Q1 25 | $3.7B | $789.2M | ||
| Q4 24 | $3.7B | $764.9M | ||
| Q3 24 | $3.6B | $732.5M | ||
| Q2 24 | $3.5B | $706.5M | ||
| Q1 24 | $3.4B | $856.2M |
| Q4 25 | $8.4B | $2.2B | ||
| Q3 25 | $8.4B | $2.2B | ||
| Q2 25 | $8.4B | $2.1B | ||
| Q1 25 | $8.4B | $2.0B | ||
| Q4 24 | $8.4B | $2.2B | ||
| Q3 24 | $8.5B | $2.1B | ||
| Q2 24 | $8.3B | $2.0B | ||
| Q1 24 | $8.4B | $2.2B |
| Q4 25 | 0.94× | 0.66× | ||
| Q3 25 | 0.99× | 0.65× | ||
| Q2 25 | 1.05× | 0.70× | ||
| Q1 25 | 1.06× | 0.75× | ||
| Q4 24 | 1.08× | 0.78× | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 1.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.0M | $114.1M |
| Free Cash FlowOCF − Capex | $134.0M | — |
| FCF MarginFCF / Revenue | 16.3% | — |
| Capex IntensityCapex / Revenue | 7.0% | — |
| Cash ConversionOCF / Net Profit | 3.89× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $396.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.0M | $114.1M | ||
| Q3 25 | $249.5M | $137.3M | ||
| Q2 25 | $113.5M | $137.2M | ||
| Q1 25 | $140.4M | $-117.5M | ||
| Q4 24 | $176.1M | $133.0M | ||
| Q3 24 | $197.2M | $91.8M | ||
| Q2 24 | $111.2M | $107.0M | ||
| Q1 24 | $147.2M | $-125.2M |
| Q4 25 | $134.0M | — | ||
| Q3 25 | $182.8M | — | ||
| Q2 25 | $47.0M | — | ||
| Q1 25 | $32.4M | — | ||
| Q4 24 | $68.6M | — | ||
| Q3 24 | $115.0M | — | ||
| Q2 24 | $51.9M | — | ||
| Q1 24 | $80.6M | — |
| Q4 25 | 16.3% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 6.4% | — | ||
| Q1 24 | 10.4% | — |
| Q4 25 | 7.0% | — | ||
| Q3 25 | 8.3% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | 14.0% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 7.3% | — | ||
| Q1 24 | 8.6% | — |
| Q4 25 | 3.89× | 3.39× | ||
| Q3 25 | 3.54× | 1.91× | ||
| Q2 25 | 2.15× | 3.49× | ||
| Q1 25 | 2.23× | -5.66× | ||
| Q4 24 | 1.72× | 4.36× | ||
| Q3 24 | 2.54× | 4.72× | ||
| Q2 24 | 1.64× | — | ||
| Q1 24 | 3.25× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
